ResearcherJiangsu Hengrui Medicine (China)Active in the last 2 years

Huan Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1732-9203; OpenAlex author ID A5100771146. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 14

Papers, trials and grants by year

2025: 2 papers

Papers 2

Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancrea… Co-author DOI 10.1186/s12916-025-04234-4 ↗
Neutrophil-albumin ratio and multi-phase computed tomography for lymph node metastasis in pancreatic cancer. Co-author DOI 10.4251/wjgo.v17.i12.113879 ↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zhongwei Sun · 1 shared paper, 2025 · strength 0.33
- Paper Neutrophil-albumin ratio and multi-phase computed tomography for lymph node metastasis in pancreatic cancer. DOI 10.4251/wjgo.v17.i12.113879 ↗
Xue Yang · 1 shared paper, 2025 · strength 0.18
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4 ↗
Xiaoyu Yin · 1 shared paper, 2025 · strength 0.18
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4 ↗
Tongsen Zheng · 1 shared paper, 2025 · strength 0.18
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4 ↗
Xianze Wang · 1 shared paper, 2025 · strength 0.18
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4 ↗
Qiang Xu · 1 shared paper, 2025 · strength 0.18
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4 ↗
Chuntao Gao · 1 shared paper, 2025 · strength 0.18
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4 ↗
Zhihua Li · 1 shared paper, 2025 · strength 0.18
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4 ↗
Tao Xia · 1 shared paper, 2025 · strength 0.18
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4 ↗
Yuejuan Cheng · 1 shared paper, 2025 · strength 0.18
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4 ↗
Heshui Wu · 1 shared paper, 2025 · strength 0.18
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4 ↗
Rufu Chen · 1 shared paper, 2025 · strength 0.18
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4 ↗
Deliang Fu · 1 shared paper, 2025 · strength 0.18
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4 ↗
Wenming Wu · 1 shared paper, 2025 · strength 0.18
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.